| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 364.80 | 33.0% |
| Total Income | 364.80 | 33.0% |
| Expenditure | 354.80 | 31.0% |
| PBT | -14.20 | 24.1% |
| Net Profit | -16.80 | 31.4% |
| OPM | 2.74% | 1.50pp |
| NPM | -4.61% | 4.33pp |
| EPS | -1.29 | 31.8% |
INNOVATE Corp.: Q1 2026 Revenue Up 33% to $364.8 Million
15 May 2026 · 15 May, 1:49 am
Summary
INNOVATE Corp. announced its first quarter 2026 results, reporting a 33.0% increase in consolidated revenue to $364.8 million. The net loss attributable to common stockholders decreased to $17.2 million, and Adjusted EBITDA increased to $19.7 million. The revenue increase was primarily driven by the Infrastructure segment. Management is encouraged by progress on strategic opportunities that position the business for improved performance in 2026.
Key Highlights
- 1
INNOVATE Corp. reported a 33.0% increase in consolidated revenue to $364.8 million for the first quarter of 2026, compared to $274.2 million in the prior year quarter.
- 2
The company's net loss attributable to common stockholders decreased by 30.6% to $17.2 million, or $1.29 per fully diluted share.
- 3
Total Adjusted EBITDA increased significantly by 173.6% to $19.7 million, compared to $7.2 million in the prior year quarter.
- 4
DBM Global Inc. reported a 35.1% increase in first quarter revenue to $357.9 million.
- 5
MediBeacon received the CE mark for the Transdermal GFR Monitor and Reusable Sensor.
- 6
R2 Technologies, Inc. reported a 58.6% increase in gross system sales outside North America compared to the prior year quarter.
- 7
DBMG's reported backlog was $1.6 billion and adjusted backlog was $1.8 billion as of March 31, 2026.
Management Comments
Avie Glazer
INNOVATE delivered a strong start to the year, with solid execution and improving visibility across the portfolio. Infrastructure performed well in the first quarter, supported by healthy sales performance, strong backlog and pipeline, and continued opportunities in the technology-related construction markets that are concentrated around AI infrastructure, energy systems, advanced manufacturing, and digital connectivity. In Life Sciences, MediBeacon received CE mark approval for the Transdermal GFR Monitor and Reusable Sensor in Europe, while R2 continued to expand internationally. We also made progress in Spectrum through successful collaborative trials, supporting potential market launches in the second half of 2026.
Paul Voigt
We continue to advance our strategic priorities and strengthen the foundation of the Company. DBM Global exited the quarter with strong momentum, supported by a robust pipeline and early progress building 2027 backlog, reinforcing confidence in sustained revenue and potential upside. In Life Sciences, MediBeacon achieved key regulatory and commercial milestones, including CE Mark approval of the Transdermal GFR Monitor and Reusable Sensor in Europe and growing momentum with key academic medical centers, while R2 continued to expand internationally. At Spectrum, despite near‑term advertising pressures, we are encouraged by progress on strategic opportunities that position the business for improved performance in 2026.
Informational and educational content only. Not investment advice.